GLASGOW—Intravesical botulinum toxin may be an effective treatment for overactive bladder (OAB) without detrusor overactivity (DOA) on urodynamic assessment, a study found.
Intravesical botulinum toxin injections are an established therapy for OAB, but most studies have focused on patients with DOA, according to investigators at Nottingham University Hospitals in Nottingham, U.K. Up to 66% of patient with OAB, however, lack this finding, the researchers noted.
In the study, the first 106 OAB patients were treated with onabotulinum toxin A and another 32 were treated with abobotulinum toxin A. Twenty-seven patients did not have DOA, whereas the others had either idiopathic or neurogenic OAB. The researchers evaluated outcomes at a three-month follow-up visit. Treatment was considered successful if patients reported improvement and requested no alternative treatment.
The treatment success rate was comparable for patients with idiopathic and neurogenic DOA and for those without DOA (81%, 93%, and 89%, respectively), according to data presented at the International Continence Society annual meeting.
Success rates were comparable between the groups treated with onabotulinum toxin A and abobotulinum toxin A.